Pivotal Therapeutics Inc.
) recently announced encouraging top line data from the REVEAL
study (n=110) on its cardiovascular candidate Vascazen in the US.
Vascazen was successful in achieving the primary objective of the
study of correcting Omega-3 deficiency.
BIODEL INC (BIOD): Free Stock Analysis Report
PIVOTAL THERAPT (PVTTF): Get Free Report
ROCHE HLDG LTD (RHHBY): Get Free Report
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.
Results from the study also revealed that Vascazen gained
statistical significance in several other secondary objectives in
patients having elevated triglycerides. The REVEAL trial is a
randomized, double blind, placebo controlled, multi-center study.
Pivotal Therapeutics enrolled 110 patients for the study.
The study evaluated the effects of Vascazen in the correction of
Omega-3 deficiency in patients suffering from cardiovascular
disease and having one or more risk factors associated with it.
Moreover, the concomitant effects of Vascazen on cardiovascular
risk factors including triglycerides, very-low-density
lipoprotein (VLDL) cholesterol, low-density lipoprotein (LDL)
cholesterol, and high-density lipoprotein (HDL) cholesterol among
others, were also evaluated.
Pivotal Therapeutics stated in its press release that the
positive top line data from the REVEAL study on Vascazen has been
accepted for presentation at the American Heart Association's
Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2013
Scientific Sessions (ATVB).
We note that the cardiovascular market currently includes big
We note that Vascazen is the lead product at Pivotal
Therapeutics. Vascazen is formulated to meet the dietary Omega-3
deficient needs of patients suffering from cardiovascular
Pivotal Therapeutics currently carries a Zacks Rank #3 (Hold).
Meanwhile other speciality pharmaceutical companies such as
) currently look better positioned. Biodel carries a Zacks Rank